Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12621119 | 1.00 | L3MBTL1 (0.49) | L3MBTL1HTTALDH1A1HRH3KMT2A | |
| SCHEMBL12621117 | 1.00 | L3MBTL1 (0.49) | L3MBTL1HTTALDH1A1HRH3KMT2A | |
| SCHEMBL14268213 | 0.94 | L3MBTL1 (0.44) | L3MBTL1HTTALDH1A1HRH3KMT2A | |
| SCHEMBL21555135 | 0.92 | L3MBTL1 (0.43) | L3MBTL1HTTALDH1A1HRH3KMT2A | |
| SCHEMBL19261541 | 0.87 | L3MBTL1 (0.37) | L3MBTL1HTTALDH1A1HRH3 | |
| SCHEMBL19223121 | 0.87 | L3MBTL1 (0.37) | L3MBTL1HTTALDH1A1HRH3 | |
| SCHEMBL20755956 | 0.84 | HRH3 (0.41) | L3MBTL1HTTHRH3KMT2AMEN1 | |
| SCHEMBL12058986 | 0.84 | HTT (0.47) | L3MBTL1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL12859381 | 0.84 | L3MBTL1 (0.46) | L3MBTL1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL10453847 | 0.83 | SLC6A9 (0.41) | L3MBTL1HTTALDH1A1HRH3SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230543-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-5017724-A | Antihypoxic, CNS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0267024-B1 | HYDROFLUORENE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| EP-0267024-A2 | Hydrofluorene derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | L3MBTL1 4810/4885HTT 805/4885ALDH1A1 4407/4885 |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | L3MBTL1 4810/4885HTT 805/4885ALDH1A1 4407/4885 |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | L3MBTL1 4587/4885HTT 4191/4885ALDH1A1 1744/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | L3MBTL1 4137/4885HTT 3638/4885ALDH1A1 4790/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | L3MBTL1 3562/4885HTT 4101/4885ALDH1A1 3225/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | L3MBTL1 1897/4885HTT 3193/4885ALDH1A1 2369/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | L3MBTL1 4137/4885HTT 3638/4885ALDH1A1 4790/4885 |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | PRKACB, PRKACG, PRKACA | L3MBTL1 1848/4885HTT 1462/4885ALDH1A1 3176/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | L3MBTL1 4559/4885HTT 4494/4885ALDH1A1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.